explore -WSS

explore

author：entertainment 2025-09-30 00:48:17 - browse：3

ANDREW YATES/AFP via Getty Images

In patients with stage 3 lung cancer where a particular genetic mutation is present in the tumor, taking AstraZeneca’s cancer-fighting pill Tagrisso reduced the chance that disease would progress by 84%.

“This will be practice changing as soon as this becomes available,” said David R. Spigel, chief scientific officer of the Sarah Cannon Research Institute at a press conference announcing the results at the annual meeting of the American Society of Clinical Oncology. “This will be how patients are treated wherever they can get access to this drug.”

Spigel but was not involved in the Tagrisso study but has relationships with multiple drugmakers including AstraZeneca.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Patients, doctors are clashing about side effects of hormonal birth control

WSS

Biogen nominates mother of director’s child to replace him on board

Patients, doctors are clashing about side effects of hormonal birth control

Inside the rise of 'mukbang' eating videos

Reanimated hearts work just as well for transplants, study finds

U.K. agency declines to back Eli Lilly’s Mounjaro for type 2 diabetes

Living organ donors deserve priority status for transplants

focus

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

leisure time

Trump demands the U.S. pay no more for drugs than other countries … again

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

The cancer drug shortage isn’t new — and neither are the solutions

Why palliative psychiatry is worth discussing

BioMarin wins approval for gene therapy to treat hemophilia A

PBM reform efforts get punted in Congress

Psychedelics group wrestles with new pharma identity

Mom launches Girl Scout troop for LGBTQ youth in Texas

As demand for Covid shots wanes, Moderna seeks its next success

Can medical device makers keep up in the race to treat obesity?

entertainment

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

Over 1,300 arrested in France in 4th night of protests over fatal police shooting of teen Nahel M.

Science's Marcia McNutt, trailblazer for women, encounters sexism scandal

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

Inside the rise of 'mukbang' eating videos

U.K. agency declines to back Eli Lilly’s Mounjaro for type 2 diabetes

hotspot

Wikipedia

hotspot

hotspot